For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

Eli Lilly's Q2 earnings soared, fueled by Mounjaro and Zepbound's impressive sales, leading to raised full-year guidance.

Eli Lilly shares fell after orforglipron's Phase 3 data showed less weight loss than rival drugs, despite a strong Q2 ...

For comparison, Lilly's arch-rival in the weight-loss category, Novo Nordisk, is developing an oral formulation of ...

US stock futures edged higher on Thursday as President Trump's sweeping tariffs hit dozens of US trade partners after his ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

People taking the new wonder drug orforglipron lost an average of 12.4 per cent of their body weight after 72 weeks and ...

Eli Lilly said on Thursday that its experimental GLP-1 pill helped patients lose 12.4% of their body weight after 72 weeks in ...

People with obesity who took Eli Lilly's daily oral GLP-1 drug orforglipron lost an average of 12.4% of their body weight, ...

Chief Executive David Ricks said the quarter was marked by robust sales for Zepbound and Mounjaro, in addition to momentum across other key medicines. Eli Lilly logged net income of $5.66 billion, or ...